| Title |
Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash
|
|---|---|
| Published in |
Supportive Care in Cancer, February 2017
|
| DOI | 10.1007/s00520-017-3623-x |
| Pubmed ID | |
| Authors |
Jesper Grau Eriksen, Inger Kaalund, Ole Clemmensen, Jens Overgaard, Per Pfeiffer |
| Abstract |
Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-induced rash. Thirty patients were included in this double-blinded placebo-controlled trial. Patients receiving cetuximab 500 mg/m(2) every second week plus chemotherapy for metastatic cancer were included. In each patient, vitamin K3 cream and placebo were applied twice daily on two separate areas of the skin of minimum 10 × 10 cm for up to 2 months. Papulopustular eruptions were evaluated clinically and monitored by clinical photos. Skin biopsies, from ten patients taken before and after 1 month of treatment from each treatment area, were stained for EGFR and pEGFR. Application of vitamin K3 cream twice daily during treatment with cetuximab did not reduce the number of papulopustular eruptions, and this was independent of the use of systemic tetracycline. No significant changes in the staining of EGFR or pEGFR were observed in the skin of the vitamin K3-treated area compared to the placebo area. The present data do not support any clinical or immunohistochemical benefit of using vitamin K3 cream for cetuximab-induced rash. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 3 | 16% |
| Student > Doctoral Student | 2 | 11% |
| Student > Ph. D. Student | 2 | 11% |
| Professor > Associate Professor | 2 | 11% |
| Lecturer | 1 | 5% |
| Other | 4 | 21% |
| Unknown | 5 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 32% |
| Biochemistry, Genetics and Molecular Biology | 3 | 16% |
| Nursing and Health Professions | 2 | 11% |
| Psychology | 1 | 5% |
| Unspecified | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 6 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2017.
All research outputs
#18,552,700
of 22,977,819 outputs
Outputs from Supportive Care in Cancer
#3,640
of 4,635 outputs
Outputs of similar age
#335,907
of 454,480 outputs
Outputs of similar age from Supportive Care in Cancer
#69
of 84 outputs
Altmetric has tracked 22,977,819 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,635 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,480 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.